Aviceda Pipeline

Unlocking a New Era of Glyco-Immune Therapeutics

At Aviceda, we are actively focused on developing advanced therapies to provide safe and significant clinical benefits to patients. We have multiple targets under investigation across several therapeutic areas. Our lead ocular asset for Geographic Atrophy AVD-104 has fully enrolled a Phase 2b/3 trial. We are also exploring other indications, such as uveitis and retinal degenerative diseases.